A Namenda monitoring checklist should track dosing, missed doses, side effects, warning signs, medication interactions, and follow-up. Namenda (memantine) is a prescription drug for moderate-to-severe dementia of the Alzheimer's type, so monitoring focuses on safety, adherence, and observable changes. The National Library of Medicine's MedlinePlus drug information explains that Namenda treats symptoms but does not cure Alzheimer's disease. Caregivers should therefore keep practical records rather than expect the medication to stop the disease.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Checks to complete before and during titration
- What caregivers should record each day
- Missed doses and urgent warning signs
- What to review at follow-up
- Does Namenda require routine MRI monitoring?
Checks to complete before and during titration
Compare the prescription with the intended dosing schedule. For immediate-release namenda, the DailyMed prescribing information specifies a starting dose of 5 mg daily, increases of 5 mg no more often than weekly, and a studied effective dose of 20 mg per day. Contact the prescriber or pharmacist if the instructions do not match. Confirm that the prescriber has considered kidney and liver function.
Severe kidney impairment—creatinine clearance of 5–29 mL/min—requires a reduced target of 5 mg twice daily. The DailyMed label also advises caution with severe liver impairment. Provide a complete list of prescriptions, over-the-counter products, and supplements. Specifically flag dextromethorphan and sodium bicarbonate. MedlinePlus and DailyMed note that alkaline urine can markedly reduce memantine clearance, while combining Namenda with other NMDA antagonists has not been systematically evaluated.
What caregivers should record each day
Watch closely when Namenda begins and after each dose increase. The DailyMed label identifies dizziness, headache, confusion, and constipation as the most common adverse reactions occurring more often than with placebo.
Use a dated log that records: The log can show timing and patterns, but it cannot prove that Namenda caused a particular change. Bring the record to follow-up visits so the prescriber can evaluate it alongside the patient's condition and dosing history.
- The scheduled dose and whether it was actually taken
- Any dizziness, headache, confusion, or constipation
- When each symptom began and whether it followed a dose increase
- Changes in daily routine, mood, behavior, or sleep
Missed doses and urgent warning signs
Never double a missed dose. According to MedlinePlus guidance on memantine, caregivers should call the prescriber before restarting after several missed days because lower-dose re-titration may be necessary.
MedlinePlus separates symptoms that require prompt medical contact from signs requiring emergency services: Collapse, seizure, breathing trouble, and inability to awaken can also signal an overdose. Do not wait for a routine appointment when these signs appear.
- Contact a medical professional promptly for shortness of breath or hallucinations.
- Call emergency services for collapse, seizure, breathing trouble, or inability to awaken the patient.
What to review at follow-up
A follow-up visit within about four to six weeks is appropriate after starting a new dementia medication, according to the National Institute on Aging's guidance for cognitive impairment. Earlier contact is appropriate when the listed warning signs occur.
Bring the following information: Ask the prescriber which symptoms Namenda is expected to help and what changes would prompt a different plan. Because Namenda manages symptoms rather than curing Alzheimer's disease, progress should be judged against specific, realistic treatment goals.
- The dose schedule and titration dates
- Missed or uncertain doses
- The symptom and daily-function log
- An updated medication and supplement list
- Any known kidney or liver concerns
Does Namenda require routine MRI monitoring?
Routine MRI monitoring is not part of this Namenda checklist. The National Institute on Aging describes such imaging for disease-modifying anti-amyloid immunotherapies because of ARIA risk, not for Namenda, an NMDA antagonist used for symptom management.
If the patient also receives an anti-amyloid treatment, follow its separate imaging plan. Do not transfer that treatment's MRI schedule to Namenda or assume one medication's monitoring rules cover the other.
